Compass Therapeutics to Participate in Upcoming Investor Events
Rhea-AI Summary
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, has announced its participation in two major investor events in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 11:00 AM ET in New York. Additionally, Compass will participate in the Cantor Global Healthcare Conference on September 17 at 8:35 AM ET, also in New York.
Both presentations will be available via webcast, with links provided for each event. Investors and interested parties can access the webcasts through the specified URLs. The presentations will be archived for 90 days on Compass Therapeutics' Events page, allowing for extended viewing opportunities. These events provide a platform for Compass to showcase its progress in developing antibody-based therapeutics for oncology applications.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CMPX declined 4.43%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2024.
Details are as follows:
H.C. Wainwright 26th Annual Global Investment Conference
Location: New York, NY
Date: Monday, September 9, 2024
Time: 11:00am ET
Webcast Link: https://journey.ct.events/
Cantor Global Healthcare Conference
Location: New York, NY
Date: Tuesday, September 17, 2024
Time: 8:35am ET
Webcast Link: https://wsw.com/webcast/cantor
Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Communications Manager
media@compasstherapeutics.com
617-500-8099
FAQ
When is Compass Therapeutics (CMPX) presenting at the H.C. Wainwright Global Investment Conference in 2024?
What is the date and time of Compass Therapeutics' (CMPX) presentation at the Cantor Global Healthcare Conference in 2024?
How long will the webcasts of Compass Therapeutics' (CMPX) investor presentations be available for replay?
Where can investors access the webcast links for Compass Therapeutics' (CMPX) September 2024 investor events?
